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OBJECTIVES: Estimate total incremental costs from second fracture for patients with 
closed hip, vertebral, and non-hip non-vertebral (NHNV) fractures in the commer-
cially insured US population. METHODS: Patients with closed hip, vertebral, and 
NHNV fracture were identiﬁed in 2002–2008 MarketScan® Commercial Database. 
All patients were 50–64 years old at incident fracture and had data 12-month pre- and 
post-period from incident fracture. Cases experienced a subsequent fracture during 
the 12-month post-period with index date as the ﬁrst subsequent fracture date. Con-
trols had no subsequent fractures during the post-period; their index dates were 
randomly assigned based on the distribution of index dates of cases. All patients had 
12-month post-period from index date and total costs were examined during the 
12-month. Multivariate regressions controlled for demographic and clinical charac-
teristics between cases and controls. Annual costs were projected to US commercially 
insured population in 2002–2008 based on projected number of patients with second 
fractures using weights derived from the Medical Expenditure Panel Survey. RESULTS: 
A total of 4752 hip, 10,080 vertebral, and 52,734 NHNV patients met the study 
criteria, with a mean age of 58 years and 63.9% women. Average annual costs per 
person were $71,272 for cases vs. $20,828 for controls, $67,772 vs. $20,029 and 
$41,635 vs. $11,212 for the hip, vertebral, and NHNV cohort, respectively. Regres-
sion-adjusted incremental costs were $47,351, $43,238, and $23,852 for hip, verte-
bral, and NHNV fracture patients, respectively. The annual incremental costs 
associated with second fracture were projected to be $166.4 million, $199.2 million, 
and $468.8 million among patients 50–64 years old with initial hip, vertebral, and 
NHNV fracture in the US commercially insured population. CONCLUSIONS: There 
is substantial cost burden associated with second fracture on the US health care system. 
Intervention for patients after their ﬁrst fractures may help reduce the long-term 
economic and clinical burden associated with second fracture.
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OBJECTIVES: To quantify individual and national estimates of the indirect costs of 
rheumatoid arthritis (RA), using national survey data. METHODS: This was a retro-
spective study using 1996–2006 data from the Medical Expenditure Panel Survey 
(MEPS). Individuals’ self-reported health conditions were mapped to the International 
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic 
codes. Individuals with an ICD-9-CM diagnostic code of 714.xx (rheumatoid arthritis 
and other inﬂammatory polyarthropathies) were categorized as having RA. A two-part 
model was speciﬁed to estimate the probability of time lost from work and annual 
number of workdays missed due to illness, conditional on missing at least 1 workday 
among employed individuals. The annual missed workdays were combined with MEPS 
earnings information to estimate individual and national indirect costs of absenteeism. 
RESULTS: There were 312 patients with RA (mean age = 46 years; 76% female), and 
89,734 without RA (mean age = 41; 52% female). The study revealed that 67% 
(209/312) of individuals with RA missed work as compared with 58% (52,046/89,734) 
of those without RA (P = 0.0007). Among those individuals who missed work, indi-
viduals with RA had a mean annual number of missed workdays of 12.05 versus 7.92 
for individuals without RA (P = 0.0081). Per capita indirect costs associated with the 
incremental difference in annual lost workdays between those with and without RA 
was $500. The estimated national indirect costs of absenteeism associated with RA 
were $229 million per year. CONCLUSIONS: Individuals with RA have a higher 
probability of missing work and missing more workdays as compared to those without 
RA. The per capita and national annual indirect costs associated with RA are sub-
stantial. The potential of appropriate and early diagnosis and treatment of RA to 
reduce time lost from work and indirect costs for individuals with RA should be 
examined.
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OBJECTIVES: To quantify individual and national estimates of the direct medical 
costs of rheumatoid arthritis (RA), using national survey data. METHODS: This 
was a retrospective study using 1996–2006 data from the Medical Expenditure Panel 
Survey (MEPS). Individuals’ self-reported health conditions were mapped to Inter-
national Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation (ICD-9-CM) 
diagnostic codes. Individuals with an ICD-9-CM diagnostic code of 714.xx (rheu-
matoid arthritis and other inﬂammatory polyarthropathies) were categorized as 
having RA. Health care services included prescription medications, inpatient, out-
patient, emergency room, ofﬁce, and home health visits. Total direct medical costs 
included health care costs covered within the health care system including those 
covered by health insurance plans and out-of-pocket (OOP) costs paid by individuals. 
To estimate costs, multivariable linear regression analyses were performed to compare 
individuals with and without RA. All costs were inﬂated using the medical component 
of the 2008 Consumer Price Index (CPI) and are represented in 2008 US dollars. 
RESULTS: There were 1213 individuals with RA (mean age = 58 years; 75% female) 
and 160,985 without RA, (mean age = 48 years; 58% female). Annual per capita 
health care costs for individuals with RA were more than double for those individuals 
without RA ($8955 vs. $3,925; P < 0.0001). Annual per capita OOP costs for 
individuals with RA were also higher than those of individuals without RA ($2131 
vs. $917; P < 0.0001). When combining health care and OOP costs, per capita 
direct costs increased by $11,086. The US national annual estimates of the, total 
direct medical costs (health care, OOP) for individuals with RA were $7.9 billion 
($6.36 billion, $1.54 billion). CONCLUSIONS: The direct medical costs associated 
with RA are substantial not only to health care payers but also to patients. The 
extent to which appropriate and early diagnosis and treatment of RA may reduce 
total health care costs for health care payers and individuals with these diseases 
should be examined.
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OBJECTIVES: Estimate the incremental costs from second fracture for patients with 
closed hip, vertebral, and non-hip non-vertebral (NHNV) fractures. METHODS: 
Case-control analysis estimating costs of second fracture, using patients with closed 
hip, vertebral, and NHNV fracture from 2002–2008 MarketScan® Medicare Supple-
mental Database. Patients had Medicare supplemental at incident fracture and 
12-month pre-period and follow-up period from the incident fracture. Index date 
was the ﬁrst subsequent fracture date for patients with subsequent fracture during 
the 12-month (cases); index dates for patients without subsequent fractures during 
the 12-month follow-up (controls) were randomly assigned based on the distribution 
of index dates of cases. Total costs were examined during the 12-month follow-up 
period using generalized linear models. A decomposition analysis of the incremental 
costs attributable to the second fracture was conducted to examine what proportion 
of the difference was due to different patient characteristics and what proportion 
was due to different model structures between cases and controls. RESULTS: A 
total of 40,772 hip, 39,479 vertebral, and 82,216 NHNV patients met the study 
criteria, with a mean age of 80.5 years. The rate of second fracture within 1 year 
of the initial fracture was 8.8%, 9.2%, and 8.2% for the three cohorts respectively. 
For the initial hip fracture cohort, annual costs were $34,143 vs. $15,296 for cases 
and controls; for vertebral, $35,773 vs. $16,523; for NHNV, $33,275 vs. $12,970. 
Adjusted incremental costs associated with second fractures were $18,645, $19,702, 
and $19,697 in these three cohorts respectively, and 89–94% of the incremental 
costs were due to the structural difference in estimated coefﬁcients of the models 
for cases and controls. CONCLUSIONS: Relative to patients with a single fracture, 
the average cost of patients with subsequent fracture(s) was 2–3 times higher. Effec-
tive management of ﬁrst fractures may help reduce the long-term economic and 
clinical burden.
PMS13
INCREMENTAL MEDICAL COST OF MUSCOLOSKELETAL DISORDERS IN 
THE UNITED STATES: ESTIMATES FROM 2006 MEDICAL EXPENDITURE 
PANEL SURVEY (MEPS) DATA
Atreja N1, Kamal K2, Patel BB2
1Duquesne university, pittsburgh, PA, USA, 2Duquesne University, Pittsburgh, PA, USA
OBJECTIVES: Recent medical cost estimates of musculoskeletal disorders (MSDs) as 
a group have not been calculated. This study estimates the incremental direct medical 
cost for individuals with MSDs in the United States (US). METHODS: Retrospective 
analysis was conducted using the 2006 Medical Expenditure Panel Survey (MEPS) 
data. Individuals, 18 year and older were identiﬁed using International Classiﬁcation 
of Diseases (ICD)-9 diagnosis codes 274.xx and 710.xx–739.xx for all diseases under 
MSDs. Incremental total expenditures of MSDs was estimated using a regression 
model adjusting for various factors like age, gender, geographic region, race, ethnicity, 
education, insurance status and number of medications(proxy measure for comorbid-
ity). Generalized linear and regression models were built to analyze the overall incre-
mental treatment cost of MSDs. RESULTS: Of the 105,166 individuals sampled in 
2006 MEPS data, approximately 11,129 individuals (10.58%) experienced at least 
one MSD. Majority of the individuals were females%, whites%, and 40 years and 
older. The total treatment cost for MSDs was $479.19 billion in 2006 compared to 
$193 billion in 1996. The largest cost components in 2006 were hospitalizations, 
physician visits, and prescription medications. CONCLUSIONS: With incremental 
medical expenditures estimated at $US 479 billion, individuals with MSDs utilize 
signiﬁcant amount of health care resources. The systematic assessment of MSDs and 
their associated cost is necessary to increase the awareness of MSDs prevalence in our 
population. There is a need for MSD-related intervention programs which can be 
instrumental in reducing the costly impact of MSDs on individuals’ well-being and 
productivity.
